Your Messages Inbox
Your Article Summary
See Latest ArticlesTwo-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression
Novartis, 10/01/09
Initial results from the two–year Phase III FREEDOMS study show that oral FTY720 was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing–remitting multiple sclerosis (MS) – one of the leading causes of neurological disability in young adults.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09
Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Article Search
Sponsor